ClinicalTrials.gg
CompletedNCT03364309Updated Jun 25, 2021Results posted

A Study of Ixekizumab (LY2439821) in Chinese Participants With Moderate-to-Severe Plaque Psoriasis

A Phase 3 interventional study of Ixekizumab and Placebo in Plaque Psoriasis, sponsored by Eli Lilly and Company. Completed at 17 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-06-25.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
438
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 11 studies in Skin Diseases by Eli Lilly and Company — 1 open to participants now, 1 under way, 1 of them phase 3. Skin Diseases · Eli Lilly and Company.

Enrollment
4th of 11
438 · median 286
Started
2018
the only one that year
Phase 3
9 of 11
1 open now
Registered
3rd of 11
by date

Among the 11 studies in Skin Diseases by Eli Lilly and Company, this one is the 4th largest by enrollment, is the only one that started in 2018, is one of 9 in phase 3, and was the 3rd registered.

Skin Diseases

496 studies on the registry are indexed under Skin Diseases; 77 are open to participants now.

Browse Skin Diseases studies →

Open to participants now

1 of the 11 studies in Skin Diseases by Eli Lilly and Company is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 55 Skin Diseases studies recruiting now, 27 (49%) set no upper age limit and 18 (33%) stop at 75 or younger; 20 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Skin Diseases by Eli Lilly and Company, or all of them as a file.
02

Study summary

The purpose of this study is to determine the efficacy and safety of the study drug ixekizumab in Chinese participants with moderate-to-severe plaque psoriasis.

Read the detailed description

Study I1F-MC-RHBH is a phase 3, multicenter, randomized, double-blind, placebo controlled, parallel-group study examining the effect of 2 dose regimens of ixekizumab versus placebo in participants with moderate-to-severe plaque psoriasis (Ps) during an induction dosing period with dosing for 12 weeks and the primary endpoint measured at 12 weeks, followed by a randomized, 48-week maintenance dosing period. During the maintenance dosing period, the study will evaluate the maintenance of response/remission, as well as relapse or rebound following treatment withdrawal, and response to retreatment following relapse.

03

Conditions studied

  • Plaque Psoriasis

Keywords

  • plaque psoriasis
  • ixekizumab
  • skin condition
  • skin disease
  • itching
  • psoriasis vulgaris
  • immune-mediated systemic disease
  • skin lesions
  • scaly patches
  • papules
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Present with chronic plaque Ps based on a confirmed diagnosis of chronic Ps vulgaris for at least 6 months prior to baseline.
  • Have ≥10% BSA involvement at screening and baseline.
  • Have both an sPGA score ≥3 and PASI score ≥12 at screening and baseline.
  • Are candidates for phototherapy and/or systemic therapy.

Exclusion criteria

Exclusion Criteria:

  • Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline.
  • Drug-induced psoriasis.
  • Ongoing use of prohibited treatments.
  • Have previously completed or withdrawn from this study, or have previously exposed to ixekizumab or any other biologic drug directly targeting interleukin-17 (IL-17) (such as secukinumab) or the IL-17 receptor.
  • Have concurrent or recent use of any biologic agent within or \<5 half-lives prior to baseline, whichever is longer.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
438 participants (actual)

Study arms

  • Experimental
    Ixekizumab 80mg Q4W

    Participants received starting dose of 160 milligrams (mg) Ixekizumab at week 0 followed by 80mg Ixekizumab once every four weeks (Q4W) by subcutaneous injection during induction period.

    Drug: Ixekizumab

  • Experimental
    Ixekizumab 80mg Q2W

    Participants received starting dose of 160mg Ixekizumab at week 0 followed by 80mg Ixekizumab once every two weeks (Q2W) by subcutaneous injection during induction period.

    Drug: Ixekizumab · Drug: Placebo

  • Placebo comparator
    Placebo

    Participants received placebo every two weeks (Q2W) by subcutaneous (SC)injection during induction period.

    Drug: Placebo

Interventions

  • Administered SC

    Also known as: LY2439821

  • DrugPlacebo

    Administered SC

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

    Time frame: Week 12

  2. Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)

    The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.

    Time frame: Week 12

  2. Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 12

  3. Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

    The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

    Time frame: Week 12

  4. Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4

    The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

    Time frame: Week 12

  5. Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score

    The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life. Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  6. Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement

    NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps \& fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal \& longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) \& fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed \& fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  7. Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis

    The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  8. Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement

    The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  9. Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  10. Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score

    The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  11. Change From Baseline on Patient Global Assessment of Disease Severity

    The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  12. Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement

    The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  13. Change From Baseline on the Joint Pain Visual Analog Scale (VAS)

    The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

    Time frame: Baseline, Week 12

  14. Percentage of Participants With Anti-Ixekizumab Antibodies

    Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

    Time frame: Baseline through Week 12

07

Results

Posted Jun 25, 2021

Participant flow

Responders were defined as achieving an sPGA score of 0 or 1. Non-responders were defined as having an sPGA score of \>1. Responders were monitored for relapse, relapse (loss of response) occurring after Week 12 (Visit 7) was defined as an sPGA score of ≥3. In Re-treatment (Maintenance) Period, participants who relapsed received continued treatment of ixekizumab 80 mg Q4W, regardless of their treatment assignment.

Induction Period
Participant flow — Induction Period
MilestonePBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
Started881741760000000000000000
Received at least one dose of study drug881741760000000000000000
Completed821701750000000000000000
Not completed6410000000000000000
Withdrew: Adverse event4010000000000000000
Withdrew: Withdrawal by subject1300000000000000000
Withdrew: Lost to follow-up1000000000000000000
Withdrew: Physician decision0100000000000000000
Maintenance Period
Participant flow — Maintenance Period
MilestonePBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
Started000479250100379312300000000
Received at least one dose of study drug000479250100379312300000000
Completed000380484173271700000000
Not completed00044124616264600000000
Withdrew: Withdrawal by subject0001313011200000000
Withdrew: Adverse event0000203010200000000
Withdrew: Relapsed0004374510200000000000
Withdrew: Lack of efficacy0000000013200000000
Withdrew: Death0000000010000000000
Withdrew: Lost to follow-up0000000010000000000
Withdrew: Miscellaneous0000000010000000000
Re-treatment (Maintenance) Period
Participant flow — Re-treatment (Maintenance) Period
MilestonePBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
Started0000000000024374510000
Completed000000000002426438000
Not completed0000000000001122000
Withdrew: Withdrawal by subject0000000000000111000
Withdrew: Adverse event0000000000000010000
Withdrew: Relapse0000000000001001000
Post-Treatment Followup Period
Participant flow — Post-Treatment Followup Period
MilestonePBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
Started0000000000000000113752
Completed000000000000000063440
Not completed00000000000000005312
Withdrew: Withdrawal by subject00000000000000003191
Withdrew: Adverse event0000000000000000261
Withdrew: Lost to follow-up0000000000000000020
Withdrew: Miscellaneous0000000000000000040

Outcome measures

PrimaryPercentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement
Percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants With a Static Physician Global Assessment (sPGA) Score of Clear (0) or Minimal (1) With at Least a 2 Point Improvement3.4 (0.0 to 7.2)79.9 (73.9 to 85.8)86.4 (81.3 to 91.4)
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.0001 · Odds ratio (or): 99.99 · 95% CI 33.57 to 99.99
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 99.99 · 95% CI 52.49 to 99.99
PrimaryPercentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)
Percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants Achieving a ≥75% Improvement in Psoriasis Area and Severity Index (PASI 75)8.0 (2.3 to 13.6)87.4 (82.4 to 92.3)93.8 (90.2 to 97.3)
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 79.95 · 95% CI 32.76 to 99.99
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 99.99 · 95% CI 64.87 to 99.99
SecondaryPercentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)

The sPGA is the physician's determination of the participant's Ps lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participants Ps were assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA assessed as 0, indicates complete resolution of plaque Ps.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)
Percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of Clear (0) (Remission)0.0 (0.0 to 0.0)35.6 (28.5 to 42.7)36.4 (29.3 to 43.5)
SecondaryPercentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)
Percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants Achieving a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90)2.3 (0.0 to 5.4)75.9 (69.5 to 82.2)82.4 (76.8 to 88.0)
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 99.99 · 95% CI 31.88 to 99.99
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 99.99 · 95% CI 46.96 to 99.99
SecondaryPercentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)

The PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs). For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored by itself and the scores were then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no Ps) to 72 (the most severe disease).

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
Percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)0.0 (0.0 to 0.0)29.3 (22.5 to 36.1)33.0 (26.0 to 39.9)
SecondaryPercentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4

The Itch NRS is a participant-administered, 11-point horizontal scale anchored at 0 (no itch) and 10 (worst itch imaginable). Overall severity of a participant's itching from Ps is indicated by circling the number that best describes the worst level of itching in the past 24 hours.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥4
percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants Achieving an Itch Numeric Rating Scale (NRS) ≥4 Point Reduction From Baseline for Participants Who Had Baseline Itch NRS ≥48.1 (1.3 to 14.8)76.6 (69.2 to 83.9)78.4 (71.2 to 85.6)
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Regression, Logistic · p = <0.001 · Odds ratio (or): 37.24 · 95% CI 13.68 to 99.99
  • Placebo vs Ixekizumab 80mg Q2W · Regression, Logistic · p = <0.001 · Odds ratio (or): 41.38 · 95% CI 15.09 to 99.99
SecondaryChange From Baseline in Dermatology Life Quality Index (DLQI) Total Score

The DLQI is a simple, participant-administered, 10 question, validated, quality-of-life questionnaire that covers 6 domains: symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "not at all," "a lot," and "very much," with corresponding scores of 1, 2, and 3, respectively, and unanswered ("not relevant") responses scored as "0." Totals range from 0 to 30 (less to more impairment). A score of 0 or 1 indicates no impact of disease on a participants quality of life. Least Square Mean (LS Mean) was calculated using Mixed Model Repeated Measures (MMRM) model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Dermatology Life Quality Index (DLQI) Total Score0.92 ± 0.495-8.60 ± 0.346-8.86 ± 0.343
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -9.52 · 95% CI -10.71 to -8.33
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -9.78 · 95% CI -10.96 to -8.59
SecondaryChange From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement

NAPSI is a numeric, reproducible, objective tool for evaluation of fingernail(fn) Ps. This scale is used to evaluate severity of fn bed Ps \& fn matrix Ps by area of involvement in the fn unit. fn is divided with imaginary horizontal \& longitudinal lines into quadrants. Each fn is given a score for fn bed Ps 0(none) to 4(Ps in 4 quadrants of the fn) \& fn matrix Ps 0(none) to 4(Ps in 4 quadrants in matrix), depending on presence (score of 1) or absence (score of 0) of any of the features of fn bed or matrix Ps in each quadrant.NAPSI score of a fn is sum of scores in fn bed \& fn matrix from each quadrant (maximum of 8). Each fn is evaluated, then the sum of all fn equals the total NAPSI score with a range from range 0 to 80. Higher scores indicate more severe ps. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Nail Psoriasis Severity Index (NAPSI) Score in Participants With Baseline Fingernail Involvement-1.26 ± 1.365-11.35 ± 0.967-10.07 ± 0.974
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -10.09 · 95% CI -13.38 to -6.79
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -8.81 · 95% CI -12.11 to -5.51
SecondaryChange From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis

The percentage involvement of psoriasis on each participant's body surface area was assessed by the investigator on a scale from 0% (no involvement) to 100% (full involvement), in which 1% corresponds to the size of the participant's hand including palm, fingers and thumb. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · Percent of BSA
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis
Percent of BSAPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Percent of Body Surface Area (BSA) Involvement of Psoriasis-0.36 ± 1.660-35.32 ± 1.157-36.70 ± 1.146
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -34.96 · 95% CI -38.94 to -30.98
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -36.34 · 95% CI -40.30 to -32.37
SecondaryChange From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement

The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Psoriasis Scalp Severity Index (PSSI) Score in Participants With Baseline Scalp Involvement-1.59 ± 0.787-18.33 ± 0.544-19.52 ± 0.539
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -16.74 · 95% CI -18.62 to -14.86
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -17.93 · 95% CI -19.80 to -16.05
SecondaryChange From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) Score-1.812 ± 0.54924.417 ± 0.38154.724 ± 0.3766
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 6.228 · 95% CI 4.915 to 7.541
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 6.536 · 95% CI 5.225 to 7.847
SecondaryChange From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score

The SF-36 is a participant-reported outcome measure evaluating participant's health status. It comprises 36 items covering 8 domains: physical functioning, role physical, role emotional, bodily pain, vitality, social functioning, mental health, and general health. Items are answered on Likert scales of varying lengths. Items from 8 domains contribute to the PCS. The summary scores range from 0 to 100, with higher scores indicating better levels of function and/or better health. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Medical Outcomes Study SF-36 Mental Component Summary (MCS) Score-1.233 ± 0.77983.960 ± 0.54144.129 ± 0.5342
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 5.193 · 95% CI 3.328 to 7.058
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: 5.362 · 95% CI 3.503 to 7.222
SecondaryChange From Baseline on Patient Global Assessment of Disease Severity

The Patient Global Assessment of Disease Severity is a single-item participant-reported outcome measure on which participants are asked to rate the severity of their psoriasis "today" from 0 (Clear) = no psoriasis, to 5 (Severe) = the worst their psoriasis has ever been. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline on Patient Global Assessment of Disease Severity
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline on Patient Global Assessment of Disease Severity-0.5 ± 0.12-3.1 ± 0.08-3.1 ± 0.08
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -2.6 · 95% CI -2.9 to -2.4
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -2.6 · 95% CI -2.9 to -2.3
SecondaryChange From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement

The Palmoplantar PASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no Ps) to 72. (the most severe disease) The PPASI was only assessed if participants have palmoplantar psoriasis at baseline. LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · units on a scale
Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement
units on a scalePlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline in Palmoplantar PASI (PPASI) in Participants With Baseline Palmoplantar Involvement-2.99 ± 0.861-6.34 ± 0.688-7.78 ± 0.626
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.003 · Lsmean difference: -3.35 · 95% CI -5.56 to -1.15
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = <0.001 · Lsmean difference: -4.79 · 95% CI -6.90 to -2.67
SecondaryChange From Baseline on the Joint Pain Visual Analog Scale (VAS)

The Joint Pain VAS is a participant-administered scale designed to measure current joint pain from PsA using a 100-mm horizontal VAS. Overall severity of a participant's joint pain from PsA is indicated by placing a single mark on the horizontal scale (0 = none; 100 = as severe as you can imagine). LS Mean was calculated using MMRM model includes treatment, baseline value, visit, baseline value-by-visit, and treatment-by-visit interaction as fixed factors.

Time frame:
Baseline, Week 12
Reported as:
Least squares mean · millimeter (mm)
Change From Baseline on the Joint Pain Visual Analog Scale (VAS)
millimeter (mm)PlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Change From Baseline on the Joint Pain Visual Analog Scale (VAS)-12.2 ± 9.64-39.6 ± 5.48-37.4 ± 4.75
Statistical analysis
  • Placebo vs Ixekizumab 80mg Q4W · Mixed Models Analysis · p = 0.022 · Lsmean difference: -27.4 · 95% CI -50.5 to -4.3
  • Placebo vs Ixekizumab 80mg Q2W · Mixed Models Analysis · p = 0.031 · Lsmean difference: -25.2 · 95% CI -47.8 to -2.5
SecondaryPercentage of Participants With Anti-Ixekizumab Antibodies

Percentage was calculated based on the number of evaluable participants and was calculated by number of participants with treatment-emergent positive anti-ixekizumab antibodies / number of evaluable participants \* 100%.

Time frame:
Baseline through Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Anti-Ixekizumab Antibodies
percentage of participantsPlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2W
Percentage of Participants With Anti-Ixekizumab Antibodies01912.5

Adverse events

Collected over Up to 72 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
PBO-Induction Dosing Period0/88 (0%)3/88 (3.4%)25/88 (28.4%)
IXE80Q4W-Induction Dosing Period0/174 (0%)2/174 (1.1%)89/174 (51.1%)
IXE80Q2W-Induction Dosing Period0/176 (0%)1/176 (0.6%)97/176 (55.1%)
IXE80Q4W(Res)/PBO-Maintenance Dosing Period0/47 (0%)1/47 (2.1%)24/47 (51.1%)
IXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing Period0/92 (0%)5/92 (5.4%)68/92 (73.9%)
IXE80Q2W(Res)/PBO-Maintenance Dosing Period0/50 (0%)1/50 (2%)22/50 (44%)
IXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing Period0/100 (0%)2/100 (2%)66/100 (66%)
PBO(Res)/PBO-Maintenance Dosing Period0/3 (0%)1/3 (33.3%)1/3 (33.3%)
PBO(NonResp)/IXE80Q4W-Maintenance Dosing Period1/79 (1.3%)5/79 (6.3%)58/79 (73.4%)
IXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing Period0/31 (0%)0/31 (0%)22/31 (71%)
IXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing Period0/23 (0%)1/23 (4.3%)14/23 (60.9%)
PBO(Resp)/PBO-Re-treatment (Maintenance) Period0/2 (0%)0/2 (0%)1/2 (50%)
IXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) Period0/43 (0%)1/43 (2.3%)24/43 (55.8%)
IXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period0/7 (0%)0/7 (0%)4/7 (57.1%)
IXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) Period0/45 (0%)2/45 (4.4%)27/45 (60%)
IXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) Period0/10 (0%)0/10 (0%)5/10 (50%)
PBO-Follow-up Period0/11 (0%)0/11 (0%)0/11 (0%)
IXE80Q4W-Follow-up Period0/375 (0%)7/375 (1.9%)27/375 (7.2%)
IXE80Q2W-Follow-up Period0/2 (0%)0/2 (0%)0/2 (0%)
Most frequent serious events
Showing 10 of 30
Most frequent serious events
EventPBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
HydrosalpinxReproductive system and breast disorders0/240/450/340/100/270/140/151/10/210/50/30/10/100/30/120/10/30/840/1
PneumoniaInfections and infestations0/880/1740/1760/471/920/500/1000/30/790/311/230/20/430/70/450/100/110/3750/2
Ectopic pregnancyPregnancy, puerperium and perinatal conditions0/240/450/340/101/270/140/150/10/210/50/30/10/100/30/120/10/30/840/1
Hepatic function abnormalHepatobiliary disorders0/880/1740/1760/470/920/500/1000/30/790/310/230/21/430/70/450/100/110/3750/2
Erythrodermic psoriasisSkin and subcutaneous tissue disorders2/880/1740/1760/470/920/500/1000/30/790/310/230/20/430/70/450/100/110/3750/2
Arteriosclerosis coronary arteryCardiac disorders0/880/1740/1760/470/920/500/1000/30/790/310/230/20/430/71/450/100/110/3750/2
AppendicitisInfections and infestations0/880/1740/1760/470/920/500/1000/30/790/310/230/20/430/71/450/100/111/3750/2
Type 2 diabetes mellitusMetabolism and nutrition disorders0/880/1740/1761/470/920/500/1000/30/790/310/230/20/430/70/450/100/111/3750/2
HypertensionVascular disorders0/880/1740/1761/470/920/500/1000/30/790/310/230/20/430/70/450/100/110/3750/2
InfectionInfections and infestations0/880/1740/1760/470/921/500/1000/30/790/310/230/20/430/70/450/100/110/3750/2
Most frequent other events
Showing 10 of 37
Most frequent other events
EventPBO-Induction Dosing PeriodIXE80Q4W-Induction Dosing PeriodIXE80Q2W-Induction Dosing PeriodIXE80Q4W(Res)/PBO-Maintenance Dosing PeriodIXE80Q4W(Res)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(Res)/PBO-Maintenance Dosing PeriodIXE80Q2W(Res)/IXE80Q4W-Maintenance Dosing PeriodPBO(Res)/PBO-Maintenance Dosing PeriodPBO(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q4W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodIXE80Q2W(NonResp)/IXE80Q4W-Maintenance Dosing PeriodPBO(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q4W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/PBO-Re-treatment (Maintenance) PeriodIXE80Q2W(Resp)/IXE80Q4W-Re-treatment (Maintenance) PeriodPBO-Follow-up PeriodIXE80Q4W-Follow-up PeriodIXE80Q2W-Follow-up Period
PharyngitisInfections and infestations2/885/1744/1760/475/921/506/1000/39/790/313/231/21/430/70/450/100/110/3750/2
Upper respiratory tract infectionInfections and infestations9/8825/17428/1767/4725/926/5031/1000/322/798/313/231/27/432/79/450/100/114/3750/2
Vitreous opacitiesEye disorders0/880/1740/1760/470/920/500/1001/30/790/310/230/20/430/70/450/100/110/3750/2
Blood glucose decreasedInvestigations0/880/1740/1760/470/920/500/1001/30/790/310/230/20/430/70/450/100/110/3750/2
TonsillitisInfections and infestations0/882/1742/1760/470/921/502/1000/30/790/310/230/20/432/71/451/100/111/3750/2
Injection site reactionGeneral disorders0/8813/17419/1760/4717/920/5017/1000/38/793/312/230/23/431/75/451/100/110/3750/2
Blood glucose increasedInvestigations2/884/1743/1762/473/920/502/1000/35/792/314/230/21/430/74/450/100/114/3750/2
NeutropeniaBlood and lymphatic system disorders0/880/1742/1760/473/921/501/1000/30/790/310/230/21/431/70/450/100/110/3750/2
Injection site swellingGeneral disorders0/880/1743/1760/471/920/503/1000/32/790/310/230/21/431/72/451/100/110/3750/2
NasopharyngitisInfections and infestations0/884/1748/1762/476/922/504/1000/33/791/313/230/22/431/72/450/100/111/3750/2

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(years)PlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2WTotal
Mean41.9 ± 12.3841.2 ± 11.5939.2 ± 10.5340.5 ± 11.37
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2WTotal
Female244534103
Male64129142335
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2WTotal
American Indian or Alaska Native0000
Asian88174176438
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
Region of Enrollment
Region of Enrollment(Participants)PlaceboIxekizumab 80mg Q4WIxekizumab 80mg Q2WTotal
China88174176438
08

Study locations

17 sites
  • Peking University People's Hospital
    Beijing, Beijing 100044, China
  • Peking University Third Hospital
    Beijing, Beijing 100191, China
  • Guangdong Province People's Hospital
    Guangzhou, Guangdong 510080, China
  • The Second Xiangya Hospital of Central South University
    Changsha, Hunan 410011, China
  • YanCheng First People's Hospital
    Yancheng, Jiangsu 224005, China
  • The Second Hospital of Jilin University
    Changchun, Jilin 130022, China
  • The First Hospital of China Medical University
    Shenyang, Liaoning 110001, China
  • The First Affiliated Hospital with Nanjing Medical University
    Nanjing, Nanjing 210029, China
  • The Second Affiliated Hospital of Xi'an Jiaotong University
    Xi'an, Shaanxi 710004, China
  • First Hospital of Shanxi Medical University
    Taiyuan, Shan XI 030001, China
  • West China Hospital of Sichuan University
    Chengdu, Sichuan 610041, China
  • Second Affiliate Hospital of Zhejiang Medical University
    Hangzhou, Zhejiang 310009, China
  • Zhejiang Provincial People's Hospital
    Hangzhou, Zhejiang 310014, China
  • Beijing Chao Yang Hospital
    Beijing, 100020, China
  • Peking University First Hospital
    Beijing, 100034, China
  • Ruijin Hospital Affiliated to Shanghai Jiao Tong University
    Shanghai, 200025, China
  • Shanghai Dermatology Hospital
    Shanghai, 200443, China
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.

Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2018 to primary completion in Jun 2020, 25 months.

Results were first posted in Jun 2021, 1 year after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Skin Diseases, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 26. This study's 25 months is above that.

Counting every sponsor, half of 60 studies reached it within 19 months; a quarter within 13 and three quarters within 26.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Dec 6, 2017
StartActual
Apr 26, 2018
Primary completionActual
Jun 4, 2020
CompletionActual
Jun 4, 2020
Results first posted
Jun 25, 2021
Last update
Jun 25, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03364309
Responsible party
Sponsor
First posted
Dec 6, 2017
Start date
Apr 26, 2018
Primary completion
Jun 4, 2020
Completion
Jun 4, 2020
Results posted
Jun 25, 2021
Last update
Jun 25, 2021

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ixekizumab

Start the discussion